John Maraganore and Clive Meanwell are launching Corsera Health out of stealth - which, through a combo of predictive diagnostics and an RNAi targeting PCSK9 and angiotensinogen, aims extend lifespans

Launched publicly today, and funded with $50M at this point, Corsera Health hopes to target those who are most at risk for atherosclerotic cardiovascular disease from an early age. The goal is to extend lives with an annual medicine by lowering LDL and blood pressure.